Vertex Pharmaceuticals Incorporated (BMV:VRTX)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Trikafta / Kaftrio Revenue	10.31B	10.24B
Trikafta / Kaftrio Revenue Growth	0.72%	14.47%
Alyftrek Revenue	837.80M	-
Casgevy Revenue	115.80M	10.00M
Casgevy Revenue Growth	1058.00%	-
Journavx Revenue	59.60M	-
Other Product Revenue	820.10M	781.50M
Other Product Revenue Growth	4.94%	-15.47%
Net Product Revenue	11.97B	11.02B
Net Product Revenue Growth	8.63%	11.66%
Other Collaborative and Royalty Revenue	30.70M	-
Revenue (Total)	12.00B	11.02B
Revenue (Total) Growth	8.90%	11.66%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Other Collaborative and Royalty Revenue	30.70M	-
United States Product Revenue	7.55B	6.68B
United States Product Revenue Growth	12.92%	10.67%
Outside of United States Product Revenue	4.45B	4.34B
Outside of United States Product Revenue Growth	2.71%	13.23%
Revenue (Other)	-30.70M	-
Revenue (Total)	12.00B	11.02B
Revenue (Total) Growth	8.90%	11.66%

Updated Dec 31, 2025. Data Source: Fiscal.ai.